Daily scan of every earnings reaction moving 20% or more, either direction. Ranked within each column by mismatch -- overreactions and mixed calls first, clean justified moves last -- so the ones worth reading first are on top.
| Ticker | Move | Price | Mkt Cap | Verdict | Sector |
|---|---|---|---|---|---|
| ★ CAPR | +86.5% | $8.16 | $379.3M | ⚠️ Overreaction | Healthcare |
| ★ SURG | +67.2% | $0.3936 | $7.9M | ⚠️ Overreaction | Technology |
| HTFL | +27.8% | $38.99 | $14.4B | ◑ Mixed | Healthcare |
| ETON | +27.0% | $52.11 | $1.4B | ✅ Justified | Healthcare |
| Ticker | Move | Price | Mkt Cap | Verdict | Sector |
|---|---|---|---|---|---|
| ★ BZAI | -32.4% | $0.8081 | $84.3M | ⚠️ Overreaction | Technology |
| ★ GAMB | -29.0% | $2.94 | $104.3M | ⚠️ Overreaction | Consumer Cyclical |
| AMPG | -28.2% | $4.39 | $92.1M | ⚠️ Overreaction | Technology |
| XOS | -22.5% | $2.00 | $18.7M | ⚠️ Overreaction | Industrials |
| VERI | -20.8% | $1.18 | $74.6M | ⚠️ Overreaction | Technology |
| KLC | -28.1% | $3.55 | $420.1M | ◑ Mixed | Consumer Defensive |
| TSSI | -23.7% | $9.30 | $229.7M | ◑ Mixed | Technology |
| INV | -47.2% | $2.09 | $113.8M | ✅ Justified | Financial Services |
| SSTI | -25.0% | $6.48 | $82.6M | ✅ Justified | Technology |
CAPR — Capricor Therapeutics, Inc. (+86.5%)
Capricor reported a Q2 2026 EPS of −$0.70 per share, missing estimates of −$0.5889 by 18.9%—a deterioration in losses driven by R&D expenses jumping 31% year-over-year to $28.9 million and G&A nearly tripling to $14.1 million, with no revenue recognized. The headline catalyst was the July 29 FDA Advisory Committee vote (3 in favor, 9 against) on Deramiocel for DMD cardiomyopathy, a significant setback, though the committee feedback on the HOPE-3 primary endpoint (upper limb function, p=0.029) was noted as "directionally supportive." The company retains $237.9 million in cash, maintains a 12+ month runway, and is continuing FDA engagement on "a path forward"—but the Advisory Committee outcome was explicitly not the vote the company requested, and the regulatory path remains uncertain with a pending BIMO Form 483 response and unresolved NS Pharma distribution dispute to be arbitrated post-FDA decision. An 86.5% single-day rally on a negative earnings miss, materially worsening cash burn, and a failed Advisory Committee vote—even with modest clinical support on one endpoint and cash adequacy—appears disconnected from the fundamental deterioration in near-term regulatory probability and the absence of any approval catalyst or revenue inflection.
View CAPR →SURG — SurgePays, Inc. (+67.2%)
SurgePays reported an EPS surprise of +145.5%, beating estimates of -$0.11 with actual earnings of $0.05, a meaningful turnaround from expected losses. However, the company provided no revenue figures, guidance changes, or business catalysts in the available source material—only the EPS beat itself. A 67% stock rally on a single earnings metric that swung from a small loss to a small profit lacks supporting detail about the scale of the business, growth trajectory, or forward guidance that would justify such a dramatic revaluation. Without context on revenue performance, margin expansion, or forward-looking catalysts, a near-doubling of stock price on a $0.16 per-share beat appears divorced from the underlying business narrative.
View SURG →HTFL — Heartflow, Inc. Common Stock (+27.8%)
Heartflow reported a Q2 EPS beat of 47.6% (actual –$0.07 vs. estimate –$0.13) and revenue of $64.1M, beating the $56.6M estimate by 13.1%, driven by 48% YoY revenue growth and 83% gross margins. Management raised full-year 2026 guidance materially, now expecting $246–$250M revenue (40–42% growth) versus prior guidance of $228–$232M (29–32% growth)—a $18M midpoint raise representing a 7.9% upside revision—and improved non-GAAP gross margin guidance to ~82% from ~81%. The business demonstrated strong operational leverage with non-GAAP operating losses improving from –$11.5M to –$7.9M YoY, and the company has $246.8M in cash. However, a 27.8% stock rally on a 47.6% EPS beat (both from a loss-making baseline) and a 7.9% guidance raise is disproportionate; the equity move appears to price in a structural re-rating and faster path to profitability that the current print—still showing GAAP net losses and negative Adjusted EBITDA—does not yet substantiate. The guidance raise is solid but incremental, not transformational.
View HTFL →ETON — Eton Pharmaceuticals, Inc. (+27.0%)
Eton Pharmaceuticals delivered a blockbuster Q2 earnings beat with EPS of $0.35 versus $0.1474 consensus (+137% surprise) and revenue of $37.6M versus $27.1M expected (+39% beat), driven by 99% year-over-year product sales growth anchored by the successful HEMANGEOL relaunch with 95% patient conversion ahead of schedule. Management raised full-year 2026 revenue guidance from $120M+ to $145M+ (21% raise at midpoint) and raised Adjusted EBITDA margin guidance from 30% to 35%—both material uplifts that reflect accelerating execution across pediatric endocrinology (DESMODA, ALKINDI, KHINDIVI) and metabolic franchises, plus accretive M&A (ASN-001 licensed late-stage candidate, IMPAVIDO acquired). A 27% stock rally on a 137% EPS beat, a 21% guidance raise, and demonstrable portfolio momentum (11 commercial products, five late-stage candidates, multiple near-term catalysts including H1 2027 KHINDIVI approval and 2027 ASN-001 NDA submission) reflects justified enthusiasm for a rare-disease pure-play executing on growth and margin expansion simultaneously.
View ETON →BZAI — Blaize Holdings, Inc. (-32.4%)
BZAI reported a modest EPS beat of 17.6% (−$0.14 actual vs. −$0.17 estimate) but missed revenue expectations by 2.4% ($11.99M vs. $12.28M estimate), a $300K shortfall. The company posted its first earnings as a public company with a loss and subpar top-line performance, yet neither metric represents a material deterioration—the EPS surprise was actually favorable and the revenue miss was within noise for a sub-$12M quarterly result. The absence of any reported guidance cut, major contract loss, competitive warning, or disclosed strategic shift in the available news coverage suggests the 32.4% stock collapse is severely disconnected from the underlying earnings reality. A -2.4% revenue miss and a positive EPS surprise should not typically trigger a one-third wipeout unless significant forward guidance or balance-sheet issues were disclosed; the sources provided contain no such catalyst.
View BZAI →GAMB — Gambling.com Group Limited (-29.0%)
Gambling.com Group (GAMB) fell 29% on earnings that showed a massive EPS miss (−$0.13 actual vs. −$0.04 estimate, a −225% surprise) but essentially matched revenue expectations ($37.8M actual vs. $37.5M estimate, +0.6% beat). While the EPS deterioration is concerning—swinging to a much larger loss than anticipated—the company delivered virtually flat revenue performance relative to consensus, indicating no material business acceleration or deceleration. A 29% single-day drop implies the market repriced the stock for either a fundamental business breakdown or severe forward guidance cut; however, the earnings report itself contains no guidance change, strategic update, or operational catalyst documented in available sources. The sheer magnitude of the stock decline appears disproportionate to a EPS miss that, though significant, occurred against a backdrop of an otherwise in-line revenue report with no disclosed forward guidance warning.
View GAMB →AMPG — AmpliTech Group, Inc. (-28.2%)
AmpliTech reported strong Q2 2026 operational results: revenue of $8.07M grew 50.9% sequentially from Q1 and gross profit surged 161.2% year-over-year to $2.25M, with gross margin expanding to 27.9% from 7.8% in Q2 2025. The company also reported $21.92M in gross proceeds from a rights offering closing post-quarter, $6M+ in follow-on orders received in July alone (including ~$4M from a North American mobile network operator LOI), and strengthened working capital to $22.93M with a 3.76x current ratio. However, net loss widened to -$3.09M from -$1.77M year-over-year due to R&D investments ($1.37M, up from $0.66M) and elevated SG&A spend, signaling near-term profitability pressure despite top-line momentum. A 28% stock decline on a quarter showing 51% sequential revenue growth, 161% gross profit expansion, a large capital raise, and multiple new orders appears disproportionate to the actual deterioration in unit economics—the loss widening is largely attributable to deliberate pre-commercialization investments rather than operational failure.
View AMPG →XOS — Xos, Inc. (-22.5%)
Xos reported a massive revenue miss—generating $4.7 million versus a $14.3 million estimate (a 67% shortfall)—driven by deliberate delivery deferrals into later quarters rather than cancellations, management stated. The EPS miss was trivial at −3.8% (−$0.55 actual vs. −$0.53 estimate). However, management highlighted genuine operational progress: H1 2026 gross margin expanded to 31.0% from 11.8% YoY, operating expenses fell 8.6%, adjusted EBITDA improved 38.6%, and the company launched the Power Hub targeting high-margin data-center demand with 250+ MWh deployed. The 2026 guidance revision (from prior undisclosed levels to $35–$43M revenue, 250–350 unit deliveries) reflects lower near-term volume but confirms management's pivot toward higher-margin products rather than a demand collapse. A 22.5% single-day drop for a small-cap loss-making company is substantial but understandable given the Q2 revenue cliff; however, the dramatic margin expansion, improved EBITDA, and management's explicit framing of deferrals (not cancellations) suggest investors may be overweighting the near-term revenue timing miss relative to the durability of the operational model and longer-term margin trajectory.
View XOS →VERI — Veritone, Inc. (-20.8%)
Veritone reported a near-flat EPS beat of +0.3% (–$0.1102 vs. –$0.1106 estimate) but crushed on revenue, missing by 14.2% ($24.3M actual vs. $28.3M estimate), driven by weaker-than-expected Software Products Services performance. However, the company delivered modest topline growth of 4.6% YoY and 20% QoQ, expanded ARR slightly to $62M, and announced substantial cost reductions of $11.3M in annualized OpEx (11% of trailing 12-month expenses) with guidance for total cuts of 15–20% by year-end, positioning the firm for operating profitability by H1 2027. The large revenue miss and 890 bps gross margin contraction (to 63.7% non-GAAP) are legitimate concerns, reflecting a problematic mix shift toward lower-margin consumption revenue, yet the company also scored multiple strategic wins including a multi-year California Highway Patrol contract, DOE consortium membership, and multi-million-dollar VDR orders—catalysts that support forward momentum. A 20.8% stock drop on a near-flat EPS beat combined with a revenue miss, while material, appears disproportionate to the underlying cost restructuring and contract wins that position Veritone for profitability acceleration in 2027; the market is pricing in execution risk and margin pressure more severely than the near-term growth trajectory and structural OpEx improvement warrant.
View VERI →KLC — KinderCare Learning Companies, Inc. (-28.1%)
KinderCare reported a modest EPS miss of 17.1% ($0.08 adjusted vs. $0.0966 est.), essentially flat revenue miss of 0.06%, but the real story was operational deterioration masked by non-GAAP reporting: Q2 operating income collapsed 96.5% YoY to $2.4M from $68.7M, driven by $20.7M in impairment losses from 49 center closures and a $48M cost headwind (partly ERC anniversary). The company also slashed full-year adjusted EPS guidance to $0.05–$0.15 (vs. prior $0.30–$0.35 implied range), a devastating 50%+ midpoint cut, and trimmed adjusted EBITDA to $200–$220M. While the 17% EPS miss is relatively contained, the guidance collapse, severe operational deleverage (operating margin down from 9.8% to 0.3%), ongoing center optimization via mass closures (49 centers), and 4% enrollment declines represent fundamental business deterioration that justifies material repricing—yet a 28% stock fall also prices in potential covenant concerns or liquidity stress given the $314M six-month impairment charge. The move likely reflects both the poor print and fears of deeper problems ahead, making it neither purely justified nor a full overreaction.
View KLC →TSSI — TSS, Inc. (-23.7%)
TSS reported Q2 2026 EPS of $0.05 versus a $0.0599 estimate (−16.5% miss) and revenue of $35.1M against $47.1M guidance (−25.5% miss), triggering a 23.7% stock decline. However, the miss obscures a deliberate strategic shift: Systems Integration revenue grew 46% YoY to $13.9M (39% of total revenue, up from 22%), Facilities Management surged 84%, and Gross Profit actually rose 11% to $8.0M, while Adjusted EBITDA climbed 12% to $4.5M—all reflecting higher-margin business expansion. Management explicitly attributed the total revenue decline to a intentional exit from lower-margin Procurement (down 45%), with CEO Dewan guiding for H2 strength and reaffirming 2026 Adjusted EBITDA at the upper end of a $20–22M range. The 24% sell-off appears disproportionate to a business executing a profitable mix shift (EBITDA up despite revenue down 20%), though the magnitude of the revenue miss versus guidance and the near-term $17M capital investment weighed against near-term earnings may have spooked growth investors expecting smoother top-line trajectory.
View TSSI →INV — Innventure, Inc. (-47.2%)
Innventure reported Q2 2026 revenue of $953k versus an estimate of $1.97M (a 52% miss), with EPS of -$0.32 versus an estimated -$0.23 (37% worse-than-expected loss per share). More critically, management suspended previously communicated 2026 revenue and cash flow targets for its flagship Accelsius division, citing evolving market dynamics including power availability constraints, GPU access limitations, and delayed deployment timing for smaller early adopters—factors that directly undermine near-term monetization despite management's stated long-term conviction in two-phase liquid cooling demand. A 47% stock decline on a revenue miss of this magnitude (51 percentage points below expectations) combined with an explicit forward guidance withdrawal and acknowledgment of near-term headwinds is proportionate to the magnitude of the business deceleration revealed. The company's accumulated deficit has widened to $418.9M and cash declined sharply to $41.5M, signaling cash burn pressure in a pre-commercialization phase where revenue generation is now described by management as an "imprecise reflection" of progress—effectively admitting the path to scaled adoption remains uncertain and capital-intensive.
View INV →SSTI — SoundThinking, Inc. (-25.0%)
SoundThinking reported a Q2 EPS miss of -46.1% (actual -$0.37 vs. estimate -$0.25) alongside revenue that fell $1.88M short of consensus ($23.9M actual vs. $25.8M expected, a 7.3% miss), but the real damage came from dramatically slashed full-year guidance: FY2026 revenue cut from $109–111M to $99–100M (a 9.2% midpoint reduction), Adjusted EBITDA margin halved from 16–18% to 8–9%, and ARR expectations lowered from $110M to over $100M. The culprit was explicit—$2.2M in customer non-renewals and renewal delays plus $0.9M in other reductions—while Adjusted EBITDA collapsed 66% year-over-year to $1.2M (5% margin vs. 13% prior year). Management attributed weakness to a "more challenging macro and procurement environment" and acknowledged softening in the critical Chicago contract pipeline, though they maintained that long-term growth drivers remain intact. A 25% stock decline is proportionate to guidance cuts of this magnitude combined with gross margin compression (48% vs. 53%) and concrete evidence of customer churn; the miss alone might justify 10–15% downside, but the forward guidance reset—implying both near-term revenue pressure and a profitability cliff—fully supports the severe reaction.
View SSTI →